scholarly journals Long term treatment with metformin and risk of vitamin B12 deficiency. A cross-sectional study in outpatients with type 2 diabetes or impaired glycemic regulation

2018 ◽  
Vol 21 (4) ◽  
pp. 269
Author(s):  
Pozzuoli, G.M.
Keyword(s):  
Vitamin B12 Deficiency ◽  
Cross Sectional Study ◽  
Term Treatment ◽  
Sectional Study ◽  
Cross Sectional ◽  
Long Term Treatment ◽  
B12 Deficiency ◽  
Glycemic Regulation

scholarly journals Prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin: a cross-sectional study

2016 ◽  
Vol 134 (6) ◽  
pp. 473-479 ◽  
Author(s):  
Charbel Pereira Damião ◽  
Amannda Oliveira Rodrigues ◽  
Maria Fernanda Miguens Castellar Pinheiro ◽  
Rubens Antunes da Cruz Filho ◽  
Gilberto Peres Cardoso ◽  
...  
Keyword(s):  
Vitamin B12 ◽  
Vitamin B12 Deficiency ◽  
Cross Sectional Study ◽  
Diabetic Patients ◽  
Sectional Study ◽  
Cross Sectional ◽  
H2 Antagonists ◽  
H2 Antagonist ◽  
B12 Deficiency

ABSTRACT: CONTEXT AND OBJECTIVE: The prevalence of vitamin B12 deficiency varies from 5.8% to 30% among patients undergoing long-term treatment with metformin. Because of the paucity of data on Brazilian patients, this study aimed to determine the frequency of B12 deficiency and related factors among Brazilian patients with type 2 diabetes mellitus (T2DM) using metformin. DESIGN AND SETTING: Cross-sectional study at a public university hospital. METHODS: Patients with T2DM and a control group of non-diabetics were included. Serum B12 levels were measured and biochemical B12 deficiency was defined as serum levels < 180 pg/ml. Associations between B12 deficiency and age, duration of T2DM, duration of use and dosage of metformin, and use of proton pump inhibitors (PPIs) or histamine H2 antagonists were determined. RESULTS: 231 T2DM patients using metformin (T2DM-met) and 231 controls were included. No difference in the frequency of PPI or H2-antagonist use was seen between the groups. B12 deficiency was more frequent in the T2DM-met group (22.5% versus 7.4%) and this difference persisted after excluding PPI/H2-antagonist users (17.9% versus 5.6%). The factors that interfered with serum B12 levels were PPI/H2-antagonist use and duration of metformin use ≥ 10 years. Use of PPI/H2-antagonists was associated with B12 deficiency, with an odds ratio of 2.60 (95% confidence interval, 1.34-5.04). CONCLUSIONS: Among T2DM patients, treatment with metformin and concomitant use of PPI/H2-antagonists are associated with a higher chance of developing B12 deficiency than among non-diabetics.

scholarly journals Vitamin B12 Deficiency in Diabetic Patients on Metformin Therapy: A cross-sectional study from Oman

2020 ◽  
Vol 20 (1) ◽  
pp. 90
Author(s):  
Ahmed Al-Hamdi ◽  
Mohammed Al-Gahhafi ◽  
Shihab Al-Roshdi ◽  
Sanjay Jaju ◽  
Ali Al-Mamari ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Vitamin B12 ◽  
Vitamin B12 Deficiency ◽  
Cross Sectional Study ◽  
Diabetic Patients ◽  
Sectional Study ◽  
Cross Sectional ◽  
Metformin Therapy ◽  
B12 Deficiency

Objectives: This study aimed to determine the prevalence of vitamin B12 deficiency amongst diabetic patients on metformin therapy. Methods: This cross-sectional study was conducted at general clinics at the University Health Center and diabetes outpatient clinics at Sultan Qaboos University Hospital, Muscat, Oman, between January and December 2017. All Omani adults who were diagnosed with type 2 diabetes mellitus and took metformin were invited to participate in the study. The variables included in this study were age, gender, duration of diabetes, dose and duration of metformin therapy, haemoglobin and glycosylated haemoglobin level. Results: A total of 248 subjects were included (response rate = 95.4%) of which 26 (10.5%) were vitamin B12 deficient and 53 (21.4%) were borderline deficient. The mean daily dose of metformin was highest among vitamin B12 deficient group (1,981 ± 222 mg; P = 0.004). Conclusion: The prevalence of vitamin B12 deficiency is considerable among diabetic patients on metformin therapy. Further research is needed to confirm the need for routine screening and monitoring.Keywords: Type 2 Diabetes Mellitus; Prevalence; Metformin; Vitamin B12 Deficiency; Oman.

scholarly journals The Prevalence of Vitamin B12 Deficiency in Patients with Type 2 Diabetes: A Cross-Sectional Study

2009 ◽  
Vol 22 (5) ◽  
pp. 528-534 ◽  
Author(s):  
M. C. Pflipsen ◽  
R. C. Oh ◽  
A. Saguil ◽  
D. A. Seehusen ◽  
D. Seaquist ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Vitamin B12 ◽  
Vitamin B12 Deficiency ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
B12 Deficiency

scholarly journals A cross sectional study to estimate the prevalence of vitamin B12 deficiency among type 2 diabetes cases on metformin therapy: a one year study

2021 ◽  
Vol 8 (5) ◽  
pp. 657
Author(s):  
Veeranarayana Gundu ◽  
Venkata Subrahmanyam Chintha
Keyword(s):  
Type 2 Diabetes ◽  
Vitamin B12 ◽  
Vitamin B12 Deficiency ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Metformin Therapy ◽  
B12 Deficiency ◽  
One Year

Background: Type 2 diabetes mellitus is associated with long term neurological complications. Metformin usage as first line drug for longer duration is associated with Vitamin B12 deficiency. Metformin on longer usage is associated with B12 deficiency in various studies and prevalence is variable. The study aims to estimate the prevalence of Vitamin B12 deficiency and its associated risk factors among T2DM on metformin therapy.Methods: A cross sectional study for one year was conducted at Narayana Medical college a tertiary care hospital. All T2DM cases attending the department and on Metformin usage were enrolled and data of age, sex, duration of T2DM, dosage of Metformin were noted as variables. Levels of Hb1Ac and complete blood picture were noted. Statistical analysis was conducted by Statistical package for social sciences (SPSS) version 21 v and p<0.05 was considered statistically significant.Results: A total of 258 participants were enrolled of which 68 (26.36%) were B12 deficient, 46 cases (17.83%) moderately deficient and 144 (55.81%) were normal. Prevalence of Vitamin B12 in the study was 26.36%. There was a statistically significant association between Vitamin B12 levels and daily dose of metformin usage. (p>0.005)Conclusions: Our study clearly highlighted the association of Vitamin B12 deficiency among T2DM on metformin therapy. Prevalence of Vitamin B12 deficiency among T2DM patients on metformin is quite considerable and cannot be neglected. Physicians prescribing the drug should plan inclusion Vitamin B12 supplementation as regular drug in T2DM cases.

scholarly journals Sars-Cov-2 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National Cross-Sectional Study

Antibiotics ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 1039
Author(s):  
Carmen Marina Meseguer Barros ◽  
Natalia Alzueta Isturiz ◽  
Rita Sainz de Rozas Aparicio ◽  
Rafael Aguilella Vizcaíno ◽  
Laura López Esteban ◽  
...  
Keyword(s):  
Respiratory Diseases ◽  
Cross Sectional Study ◽  
Term Treatment ◽  
Sectional Study ◽  
Cross Sectional ◽  
Old Patients ◽  
Chronic Respiratory Diseases ◽  
Long Term Treatment ◽  
Official Data

The aim of this study was to know the prevalence and severity of COVID-19 in patients treated with long-term macrolides and to describe the factors associated with worse outcomes. A cross-sectional study was conducted in Primary Care setting. Patients with macrolides dispensed continuously from 1 October 2019 to 31 March 2020, were considered. Main outcome: diagnosis of coronavirus disease-19 (COVID-19). Secondary outcomes: symptoms, severity, characteristics of patients, comorbidities, concomitant treatments. A total of 3057 patients met the inclusion criteria. Median age: 73 (64–81) years; 55% were men; 62% smokers/ex-smokers; 56% obese/overweight. Overall, 95% of patients had chronic respiratory diseases and four comorbidities as a median. Prevalence of COVID-19: 4.8%. This was in accordance with official data during the first wave of the pandemic. The most common symptoms were respiratory: shortness of breath, cough, and pneumonia. Additionally, 53% percent of patients had mild/moderate symptoms, 28% required hospital admission, and 19% died with COVID-19. The percentage of patients hospitalized and deaths were 2.6 and 5.8 times higher, respectively, in the COVID-19 group (p < 0.001). There was no evidence of a beneficial effect of long-term courses of macrolides in preventing SARS-CoV-2 infection or the progression to worse outcomes in old patients with underlying chronic respiratory diseases and a high burden of comorbidity.

Sign in / Sign up

Export Citation Format

Share Document